# Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors

> **NCT05379946** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **InventisBio Co., Ltd** · enrollment: 92 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** D-1553
- **DRUG:** IN10018

## Key facts

- **NCT ID:** NCT05379946
- **Lead sponsor:** InventisBio Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-10-12
- **Primary completion:** 2025-07
- **Final completion:** 2025-12
- **Target enrollment:** 92 (ESTIMATED)
- **Last updated:** 2025-04-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05379946

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05379946, "Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05379946. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*